June 6-11, 2010 - Nuevo Vallarta, Mexico
| Editors: | John G. Auniņš,Merck, USA |
|---|---|
| Barry C. Buckland, BiologicB, USA | |
| Kathrin U. Jansen, Pfizer, USA | |
| Paula Marques Alves, IBET, Portugal |
The articles for these proceedings are not peer-reviewed.
Final Conference Program, Barry Buckland, John Aunins, Paula Marques Alves, and Kathrin Jansen (Article)
DEVELOPMENT OF A MULTI-DOSE FORMULATION FOR PREVNAR 13™, Lakshmi Khandke, Cindy Yang, Jingrun Fan, Hanyoung Han, Ksenia Krylova Abbas Rashidbaigi, Bruce A. Green, and Kathrin U. Jansen (Article)
APPLICATION OF ANIMAL-FREE RECOMBINANT BIOACTIVE PROTEIN SUPPLEMENTS TO IMPROVE THE PERFORMANCE OF CELL-BASED VIRAL VACCINE PRODUCTION, Kenneth Bertram, Marina Ross, Domenica Cavallaro, Larissa Chirkova, and Geoffrey Francis (Article)
ULTRA-SCALE DOWN STUDIES OF HUMAN CELL BIOPROCESSING FOR A PROSTATE CANCER VACCINE THERAPY - THE IMPACT OF CAPILLARY SHEAR, Juan Pablo Acosta Martinez, Katherine Lawrence, Carol Chu Mike Hoare, and Stephen Ward (Article)
HUMAN CELLS FOR PROSTATE CANCER VACCINE THERAPY - THE IMPACT OF CENTRIFUGATION UPON KEY PRODUCT QUALITY ATTRIBUTES, Michael Delahaye, Katherine Lawrence, Carol Chu Mike Hoare, and Stephen Ward (Article)
DESIGN OF EXPERIMENT BASED JAPANESE ENCEPHALITIS VIRUS FORMALDEHYDE INACTIVATION OPTIMISATION FOR A VERO CELL DERIVED VACCINE, Michael Hughson (Article)
A VACCINE PROTOTYPE USING BACULOVIRUS EXPRESSION SYSTEM FOR THE CONTROL OF AVIAN INFLUENZA VIRUS, Mauricio Realpe, R. Mora, L. Castellanos, F. Robles, and C. González-Hernández (Article)
DEVELOPMENT OF PROTEIN CAPSULAR MATRIX VACCINE (PCMV) TECHNOLOGY, Kevin P. Killeen, Ann Thanawastien, and Tom Griffin (Article)
PURIFICATION PROCESS DEVELOPMENT OF PROTEIN SUBUNIT BASED VACCINE CANDIDATES PRODUCED USING RECOMBINANT E. COLI EXPRESSION SYSTEM (Part - I), Davinder Chawla and Yan-Ping Yang (Article)
PURIFICATION PROCESS DEVELOPMENT OF PROTEIN SUBUNIT BASED VACCINE CANDIDATES PRODUCED USING RECOMBINANT E. COLI EXPRESSION SYSTEM (Part - II), Davinder Chawla and Yan-Ping Yang (Article)
ESCHERICHIA COLI PLASMID DNA FERMENTATION: STRAIN AND PROCESS-SPECIFIC EFFECTS ON VECTOR YIELD, QUALITY, AND TRANSGENE EXPRESSION, Aaron E. Carnes, Jeremy Luke, Justin Vincent, Clague Hodgson, and James Williams (Article)
RNA BASED PLASMID SELECTION SYSTEM FOR ANTIBIOTIC-FREE PLASMID DNA VECTOR PRODUCTION, Aaron E. Carnes, Jeremy Luke, Justin Vincent, Clague Hodgson, and James Williams (Article)
POLY-METHYL VINYL ETHER-CO-MALEIC ANHYDRIDE NANOPARTICLES AS ANTIGEN DELIVERY AND ACTIVATING SYSTEMS, Carlos Gamazo, Ibai Tamayo, and Ana I. Camacho (Article)
PRODUCTION OF SEROTYPE 6-DERIVED RECOMBINANT ADENO-ASSOCIATED VIRUS IN SERUM-FREE SUSPENSION CULTURES OF HEK 293 CELLS, Érica A. Schulze (Article)
RABIES VIRUS GLYCOPROTEIN (RVGP) EXPRESSION IN DROSOPHILA S2 CELLS AND BY SEMLIKI FOREST VIRUS (SFV). SYNTHESIS AND PROTECTION STUDIES, Carlos Pereira (Article)
ESTABLISHING A PLATFORM FOR SPRAY DRYING INHALABLE VACCINES IN SOUTH AFRICA, Willem Germishuizen, L Venter, A Khosa, F Mudau, P.B. Fourie, B Pulliam, M Kabadi, A Schiermeier, and D.A . Edwards (Article)
MANUFACTURING FLU VACCINE IN MEXICO: A MAJOR PUBLIC HEALTH AND TECHNOLOGY TRANSFER CHALLENGE, Roger Vinas (Article)
INNOVATIVE THERAPEUTIC CANCER VACCINES IN CUBA: AN UPDATE, Luis Enrique Fernández (Article)
VACCINE STABILIZATION – RESEARCH, COMMERCIALIZATION, AND IMPACT, Ray Cummings, Debra Kristensen, Dexiang Chen, and Michel Zaffran (Article)
THE GLOBAL MANUFACTURE OF POLIO VACCINE IN THE ENDGAME OF ERADICATION, Philip Minor (Article)
NEW VACCINE TECHNOLOGIES: PROMISING ADVANCES MAY SAVE MORE LIVES, John Boslego (Article)
CIM TECHNOLOGY: ENABELING ECONOMIC VACCINE PURIFICATION, Matjaz Peterka, Franci Smrekar, Tony Brazzale, Marko Banjac, Petra Kramberger, Milos Barut, Ales Podgornik, and Ales Strancar (Article)
SCALE-UP OF AN INTENSIFIED PROCESS FOR RAD35 ADENOVIRUS PRODUCTION USING THE PER.C6® CELL SUBSTRATE, Alfred Luitjens and Herman van Herk (Article)
THE CHALLENGE OF DEVELOPING NEW GENERATION VACCINES FOR CONTROL AND ERADICATION OF FOOT AND MOUTH DISEASE IN SOUTH AMERICA, Susana Levy (Article)
NIPAH/HENDRA: UNDERSTANDING THE LINKS BETWEEN HUMAN AND VETERINARY EMERGING DISEASES, Jules Minke (Article)
PROCESS SCALE-UP AND OPTIMIZATION FOR PRODUCTION OF HIGH EFFICACY ORAL RABIES VACCINE, Amine Kamen, Chun Fang Shen, Stephane Lanthier, Danielle Jacob, Johnny Montes, and Andrew Beresford (Article)
BUILDING PROCESS UNDERSTANDING FOR VACCINE MANUFACTURING USING DATA MINING, Matthew Wiener (Article)
CHALLENGES IN CONFRONTING PANDEMIC INFLUENZA USING NOVEL ADJUVANTED VACCINES, Louis F. Fries (Article)
AFTER THE LICENSE APPROVAL: HOW ANALYTICS CAN KEEP YOU IN THE MARKET, Robert Sitrin (Article)
DEVELOPMENT OF INACTIVATED POLIO VACCINE FROM ATTENUATED SABIN STRAINS FOR CLINICAL STUDIES AND TECHNOLOGY-TRANSFER PURPOSES, Yvonne E. Thomassen, Wilfried A.M. Bakker, Janny Westdijk, Aart G. Van ‘t Oever, Nico Van den Heuvel, Jan Hendriks, Gideon F.A. Kersten, and Leo A. Van der Pol (Article)
DEVELOPMENT OF RECOMBINANT PROTEIN BASED CHEMICAL CONJUGATE MALARIA VACCINES TARGETING THE PRE-ERYTHROCYTIC STAGE, TRANSMISSION BLOCKING, OR BOTH, David L. Narum, Nicholas MacDonald, David Jones, Ruth Ellis, Yimin Wu, and Patrick E. Duffy (Article)
CLINICAL DEVELOPMENT OF FORMULATED THERAPEUTIC AND PROPHYLACTIC DNA-BASED VACCINES, Alain Rolland (Article)
INFLUENCE OF HOST CELL DEFENCE DURING INFLUENZA VACCINE PRODUCTION IN MDCK CELLS, Timo Frensing, Claudius Seitz, Bjoern HeynischOtto-von-Guericke, and Udo Reichl (Article)
POTENT, RAPID AND COST-EFFECTIVE INFLUENZA VACCINES MADE IN E. COLI, Thomas Hofstaetter (Article)
ISCOMATRIX™ ADJUVANT LINKS INNATE AND ADAPTIVE IMMUNE RESPONSES, Debbie Drane (Article)